lanabecestat: Clinical Trials

3 trials of lanabecestat, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 terminated. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Terminated 3
Phase 21Terminated 1

Follow lanabecestat: new trials by email Literature Review of lanabecestat trials Research Report on lanabecestat

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia
Lanabecestat - Alzheimer's Disease
Phase 3TerminatedAstraZeneca4212017-03-152019-12-03
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
Lanabecestat, Placebo - Alzheimer's Disease
Phase 3TerminatedAstraZeneca17222016-07-012019-12-03
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
Lanabecestat, Placebo - Alzheimer´s Disease
Phase 2 / Phase 3TerminatedAstraZeneca22182014-09-302019-12-03

Conditions studied

Alzheimer Disease (3)  ·  Brain Diseases (3)  ·  Central Nervous System Diseases (3)  ·  Dementia (3)  ·  Mental Disorders (3)  ·  Nervous System Diseases (3)  ·  Tauopathies (3)  ·  Neurocognitive Disorders (2)  ·  Neurodegenerative Diseases (2)  ·  Delirium (1)

Sponsors

AstraZeneca (3)

Countries

Canada (3)  ·  France (3)  ·  Germany (3)  ·  Japan (3)  ·  Poland (3)  ·  South Korea (3)  ·  Spain (3)  ·  United Kingdom (3)  ·  United States (3)  ·  Australia (2)  ·  Belgium (2)  ·  Hungary (2)  ·  Italy (2)  ·  Puerto Rico (2)  ·  Romania (2)

Results publications

PMID 27767991, PMID 31764959, PMID 33049114, PMID 40603145

NIH funding

2014 (1), 2015 (1), 2016 (1)